ERX-11 was potent (73% reduction in tumor volume compared to control) against the growth of MCF-7-PELP1 xenografts, which overexpress PELP1 (3-fold higher than parental MCF-7) (Figure 5E). Here, PELP1 is linked to neoplasm.